May « 2015 « Science and Enterprise

Trial Testing 3-Drug Combo for Drug Resistant TB

By Alan, on May 14th, 2015%

Tuberculosis bacteria (DoE.gov)

14 May 2015. A new clinical trial is underway in South Africa testing a regimen of three drugs to treat extensively drug-resistant tuberculosis, a form of the disease that does not respond to normal or even back-up treatments. The trial is sponsored by Global Alliance for TB Drug Development, or . . . → Read More: Trial Testing 3-Drug Combo for Drug Resistant TB

Mayo Clinic, Baylor to Study Genomes for Drug Safety

By Alan, on May 13th, 2015%

DNA molecule display (Christian Guthier, Flickr)

13 May 2015. Mayo Clinic and Baylor College of Medicine are beginning a study of 10,000 human genomes to reveal drug safety problems and highlight where drugs may not work for some people. Financial aspects of the collaboration, involving Mayo Clinic’s Biobank and Baylor’s Human Genome Sequencing . . . → Read More: Mayo Clinic, Baylor to Study Genomes for Drug Safety

Biotech, Research Institute Partner on Gene Therapies

By Alan, on May 13th, 2015%

Electrostatic image of adeno-associated virus (National Institute of General Medical Sciences, NIH)

13 May 2015. A collaboration between a U.S. biotechnology company and French research institute is enhancing current techniques to allow patients with rare diseases to receive multiple doses of gene therapies. Selecta Biosciences in Watertown, Masachusetts and Généthon in Evry, France . . . → Read More: Biotech, Research Institute Partner on Gene Therapies

RNA Therapies Developer Spins-Off Rare Disease Venture

By Alan, on May 12th, 2015%

Stéphane Bancel (Brenda Bancel, Wikimedia Commons)

12 May 2015. Moderna Therapeutics, a developer of RNA-based treatments, is starting a new company to design therapies with its technology to address rare diseases. Financial details of the spin-off company Elpidera LLC, the third such venture launched by Moderna, were not disclosed.

Moderna, a biotechnology enterprise . . . → Read More: RNA Therapies Developer Spins-Off Rare Disease Venture

Gene Editing Harnessed to ID Cancer Targets

By Alan, on May 12th, 2015%

Acute myeloid leukemia cells (Cancer Genome Atlas, NIH)

12 May 2015. Researchers from Cold Spring Harbor Lab in New York developed a technique that reveals targets for leukemia drugs with an emerging gene editing technology. A team from the lab of geneticist Christopher Vakoc published its findings yesterday in the journal Nature Biotechnology . . . → Read More: Gene Editing Harnessed to ID Cancer Targets

Trial Underway Testing Sleep Apnea Stimulation Device

By Alan, on May 11th, 2015%

(Aweisenfels, Wikimedia Commons)

11 May 2015. A clinical trial testing an experimental neurostimulation device to treat obstructive sleep apnea implanted the device in its first two test patients. The trial is sponsored by ImThera Medical Inc. in San Diego, the developer of the aura6000 device being tested.

Obstructive sleep apnea is a disorder . . . → Read More: Trial Underway Testing Sleep Apnea Stimulation Device

GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

By Alan, on May 11th, 2015%

Scanning electron micrograph of HIV particles infecting a human T cell (NIH.gov)

11 May 2015. Pharmaceutical maker GlaxoSmithKline and University of North Carolina in Chapel Hill are establishing a joint research center and spin-off company to develop new treatments for HIV and AIDS. GSK says it plans to invest $20 million over 5 . . . → Read More: GSK, UNC Chapel Hill Partner on HIV/AIDS Cure

NASA Challenge Seeks Elements for Human Presence on Mars

By Alan, on May 8th, 2015%

Mars surface and atmosphere, from NASA’s Mars Atmosphere and Volatile EvolutioN, or MAVEN, mission. (NASA.gov)

8 May 2015. NASA is asking the public for ideas on ways to establish a long-term presence of Mars in a new challenge offered by InnoCentive. The competition has a total purse of $15,000 and a deadline for . . . → Read More: NASA Challenge Seeks Elements for Human Presence on Mars

Clinical Trial Testing West Nile Vaccine

By Alan, on May 7th, 2015%

(CDC.gov)

7 May 2015. A vaccine for West Nile virus, a seasonal infection spread by mosquitoes, is being tested for safety in an early stage clinical trial. The vaccine, code-named HydroVax-001, is being developed in the lab of microbiologist Mark Slifka at Oregon Health and Science University in Beaverton and commercialized by Najit . . . → Read More: Clinical Trial Testing West Nile Vaccine

Standard Devised to Cut Poultry Antibiotic Use

By Alan, on May 7th, 2015%

(Agricultural Research Service, USDA)

7 May 2015. An organization of school districts in the U.S., joined by the Pew Charitable Trusts and U.S. Department of Agriculture, wrote a set of guidelines to reduce the use of antibiotics in raising chickens destined for school feeding programs. Tyson Foods, the nation’s largest producer of chickens, . . . → Read More: Standard Devised to Cut Poultry Antibiotic Use

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise